Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Emactuzumab by SynOx Therapeutics for Tenosynovial Giant Cell Tumor: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase III for Tenosynovial Giant Cell Tumor. According to...
Emactuzumab by SynOx Therapeutics for Brenner Tumor: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Brenner Tumor. According to GlobalData, Phase...
Emactuzumab by SynOx Therapeutics for Adenocarcinoma: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II...
Emactuzumab by SynOx Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
Emactuzumab by SynOx Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Emactuzumab by SynOx Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Emactuzumab by SynOx Therapeutics for Peritoneal Cancer: Likelihood of Approval
Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...